A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study

CNS Drugs

Volumn 30, Issue 8, 2016, Pages 735-747

  Weiden, Peter J ^a,e   Manning, Raymond ^b   Wolfgang, Curt D ^c   Ryan, J Michael ^d   Mancione, Linda ^d   Han, Guangyang ^d   Ahmed, Saeed ^d   Mayo, Mallery G ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b California Neuropsychopharmacology Clinical Research Institute   (United States)

^c Vanda Pharmaceuticals   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Uptown Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPHENHYDRAMINE; ILOPERIDONE; LORAZEPAM; LOW DENSITY LIPOPROTEIN; PLACEBO; TRIHEXYPHENIDYL; ZOLPIDEM; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGED; AKATHISIA; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT WITHDRAWAL; WEIGHT GAIN; XEROSTOMIA; PROCEDURES; RECURRENT DISEASE; SECONDARY PREVENTION; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; MALE; PIPERIDINES; RECURRENCE; SCHIZOPHRENIA; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84977098572     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0345-4     Document Type: Article

References (19)

1. Fanapt (iloperidone) [prescribing information]. Washington, DC: Vanda Pharmaceuticals Inc.; 2014.
2. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 2001;25:904–14.
3. Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. Long term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr. 2013;18:43–54.
4. Weiden PJ. Iloperidone for the treatment of schizophrenia: an updated clinical review. Clin Schizophr Relat Psychoses. 2012;6:34–44.
5. Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S20–8.
6. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S12–9.
7. Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S29–35.
8. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S4–11.
9. Baroldi P, Wolfgang CD, Fisher D. A pharmacokinetic (PK)-pharmacodynamic (PD) relationship exists for efficacy of iloperidone, a novel investigational atypical antipsychotic agent. Paper presented at: American Psychiatric Association Annual Meeting, May 19–24, 2007, San Diego, CA.
10. Weiden PJ, Citrome L, Alva G, Brams M, Glick ID, Jackson R, et al. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophr Res. 2014;153:160–8.
11. Citrome L, Weiden PJ, Alva G, Glick ID, Jackson R, Mattingly G, et al. Switching to iloperidone: an omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia. Clin Schizophr Relat Psychoses. 2015;8:183–95.
12. Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol. 2013;33:3–10.
13. Lohr JB, Eidt CA, Alfaraj AA, Soliman MA. The clinical challenges of akathisia. CNS Spectr. 2015;20:4–14.
14. Shear MK, Frances A, Weiden P. Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol. 1983;3:235–6.
15. Levinson DF, Simpson GM, Singh H, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry. 1990;47:761–8.
16. Van Putten T, May PR, Marder SR. Response to antipsychotic medication: the doctor’s and the consumer’s view. Am J Psychiatry. 1984;141:16–9.
17. Hirose S. The causes of underdiagnosing akathisia. Schiz Bull. 2003;29:547–58.
18. Weiden PJ, Mann JJ, Haas G, et al. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry. 1987;144:1148–53.
19. Stahl SM. Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectr. 2013;18:285–8.